These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 35984598)

  • 1. Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors.
    Waksal JA; Mascarenhas J
    Curr Hematol Malig Rep; 2022 Oct; 17(5):140-154. PubMed ID: 35984598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel therapeutics and targets in myelofibrosis.
    Waksal JA; Harrison CN; Mascarenhas JO
    Leuk Lymphoma; 2022 May; 63(5):1020-1033. PubMed ID: 34852713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis.
    Talpaz M; Kiladjian JJ
    Leukemia; 2021 Jan; 35(1):1-17. PubMed ID: 32647323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New Treatments for Myelofibrosis.
    Tremblay D; Mesa R
    Curr Treat Options Oncol; 2023 Feb; 24(2):61-75. PubMed ID: 36640223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel treatments for myelofibrosis: beyond JAK inhibitors.
    Tremblay D; Mesa R
    Int J Hematol; 2022 May; 115(5):645-658. PubMed ID: 35182376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis.
    Tefferi A; Pardanani A; Gangat N
    Haematologica; 2023 Nov; 108(11):2919-2932. PubMed ID: 36861402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of fedratinib for adult patients with newly diagnosed and previously treated myelofibrosis.
    Saleh K; Ribrag V
    Expert Rev Hematol; 2023 Apr; 16(4):227-236. PubMed ID: 36939633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. State-of-the-Art Review on Myelofibrosis Therapies.
    Wang F; Qiu T; Wang H; Yang Q
    Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e350-e362. PubMed ID: 34903489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging drugs for the treatment of myelofibrosis: phase II & III clinical trials.
    Tremblay D; Hoffman R
    Expert Opin Emerg Drugs; 2021 Dec; 26(4):351-362. PubMed ID: 34875179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fedratinib: a pharmacotherapeutic option for JAK-inhibitor naïve and exposed patients with myelofibrosis.
    England JT; Gupta V
    Expert Opin Pharmacother; 2022 Oct; 23(15):1677-1686. PubMed ID: 36252265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Novel therapeutics in myeloproliferative neoplasms: beyond JAK inhibitors].
    Edahiro Y
    Rinsho Ketsueki; 2023; 64(9):970-980. PubMed ID: 37793873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SOHO State of the Art Updates and Next Questions: Identifying and Treating "Progression" in Myelofibrosis.
    Bose P; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):641-649. PubMed ID: 34272171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis.
    Chifotides HT; Bose P; Masarova L; Pemmaraju N; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):210-223. PubMed ID: 34840087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Utility of Fedratinib in Myelofibrosis.
    Waksal JA; Tremblay D; Mascarenhas J
    Onco Targets Ther; 2021; 14():4509-4521. PubMed ID: 34456572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent progress of JAK inhibitors for hematological disorders.
    Kirito K
    Immunol Med; 2023 Sep; 46(3):131-142. PubMed ID: 36305377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of anemia in myelofibrosis: focusing on novel therapeutic options.
    Arslan Davulcu E; Oğuz MB; Kılıç E; Eşkazan AE
    Expert Opin Investig Drugs; 2024 Jan; 33(1):27-37. PubMed ID: 38073183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacotherapeutic management of patients with myelofibrosis: looking beyond JAK inhibitors.
    Duminuco A; Vetro C; Giallongo C; Palumbo GA
    Expert Opin Pharmacother; 2023; 24(13):1449-1461. PubMed ID: 37341682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacotherapy of Myelofibrosis.
    Tremblay D; Marcellino B; Mascarenhas J
    Drugs; 2017 Sep; 77(14):1549-1563. PubMed ID: 28791654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myelofibrosis: challenges for preclinical models and emerging therapeutic targets.
    Morsia E; Gangat N
    Expert Opin Ther Targets; 2021 Mar; 25(3):211-222. PubMed ID: 33844952
    [No Abstract]   [Full Text] [Related]  

  • 20. The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib.
    Patel AA; Odenike O
    Curr Hematol Malig Rep; 2020 Dec; 15(6):409-418. PubMed ID: 32780250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.